Guidelines for diagnosis and treatment of Chinese medicine on idiopathic pulmonary fibrosis_Chinese Journal of Evidence-Based Medicine

Authors：

 Internal Medicine Committee of World Federation of Chinese Medicine Societies

Corresponding author：

Internal Medicine Committee of World Federation of Chinese Medicine Societies, Email: li_js8@163.com

Keywords：

Idiopathic pulmonary fibrosis; Traditional Chinese medicine; Clinical practice guideline

DOI：

10.7507/1672-2531.202407161

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic and interstitial lung disease of unknown cause. It has a serious impact on people's health. Traditional Chinese medicine (TCM) has certain advantages in diagnosing and treating on IPF, which have been widely used in clinic. In order to improve the diagnostic and treatment level for IPF with TCM. The Internal Medicine Committee of World Federation of Chinese Medicine Societies organized and established a multidisciplinary background working group. The document was formulated by referring to the formulation method and process of clinical practice guidelines, which are based on the best evidence and the opinions of clinical physicians and patients. Physicians can use this guideline to make clinical decisions.

1.	Maher TM, Bendstrup E, Dron L, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res, 2021, 22(1): 197.
2.	Cox IA, Otahal P, de Graaff B, et al. Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in Australia. Respirology, 2022, 27(3): 209-216.
3.	Strongman H, Kausar I, Maher TM. Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK. Adv Ther, 2018, 35(5): 724-736.
4.	Cottin V, Spagnolo P, Bonniaud P, et al. Mortality and respiratory-related hospitalizations in idiopathic pulmonary fibrosis not treated with antifibrotics. Front Med (Lausanne), 2021, 8: 802989.
5.	Gao J, Kalafatis D, Carlson L, et al. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry. Respir Res, 2021, 22(1): 40.
6.	Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med, 2018, 198(5): e44-e68.
7.	Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med, 2022, 205(9): e18-e47.
8.	Dove EP, Olson AL, Glassberg MK. Trends in idiopathic pulmonary fibrosis-related mortality in the United States: 2000-2017. Am J Respir Crit Care Med, 2019, 200(7): 929-931.
9.	Hopkins RB, Burke N, Fell C, et al. Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. Eur Respir J, 2016, 48(1): 187-195.
10.	Raimundo K, Chang E, Broder MS, et al. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med, 2016, 16: 2.
11.	Collard HR, Chen SY, Yeh WS, et al. Health care utilization and costs of idiopathic pulmonary fibrosis in U. S. Medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc, 2015, 12(7): 981-987.
12.	宣建伟, 卢永吉, 任懋东, 等. 中国特发性肺纤维化患者的直接经济负担. 中国药物经济学, 2019, 14(6): 9-12.
13.	Li J, Yu XQ, Xie Y, et al. Efficacy and safety of traditional Chinese medicine treatment for idiopathic pulmonary fibrosis: an exploratory, randomized, double-blinded and placebo controlled trial. Front Pharmacol, 2022, 13: 1053356.
14.	中华中医药学会内科分会, 中国民族医药学会肺病分会, 中华中医药学会肺系病分会. 特发性肺纤维化中医证候诊断标准(2019版). 中医杂志, 2020, 61(18): 1653-1656.
15.	张立山, 戴雁彦, 任传云. 武维屏教授治疗肺纤维化十法. 中国中医药信息杂志, 2008, 15(4): 94-95.
16.	鞠铮嵘. 肺痿理论—晁恩祥名老中医治疗肺纤维化经验总结. 北京: 北京中医药大学, 2014.
17.	李建生. 特发性肺纤维化中医辨证治疗概要. 中医学报, 2017, 32(6): 929-931.
18.	徐慧卿. 针药并用治疗特发性肺纤维化疗效观察. 上海针灸杂志, 2010, 29(10): 641-642.
19.	李戎, 闫智勇, 李文军, 等. 针灸治疗特发性肺纤维化临床观察. 针灸临床杂志, 2004, (2): 13-14,59.
20.	王艳, 谢洋, 吉紫乐, 等. 中药离子导入辅助治疗特发性肺纤维化疗效与安全性的Meta分析. 中医学报, 2023, 38(3): 665-672.
21.	白文梅, 马红霞, 同立宏. 益气活血通络膏方治疗气虚血瘀型特发性肺纤维化60例疗效观察. 新疆中医药, 2018, 36(6): 7-8.
22.	杨柳, 成淑芳, 张树森, 等. 康益膏方治疗特发性肺纤维化60例. 光明中医, 2015, 30(7): 1449-1450.
23.	张树森, 杨柳, 董瑞. 珠及膏治疗特发性肺纤维化气阴两伤型临床观察. 中国中医药现代远程教育, 2019, 17(23): 69-71.
24.	刘香玉, 李怡良, 戈艳蕾, 等. 隔姜督灸联合阳和汤化裁治疗特发性肺间质纤维化临床观察. 云南中医中药杂志, 2021, 42(5): 31-34.
25.	周剑, 吴炳辰. 热敏灸联合药物对肺肾气虚型特发性肺纤维化患者肺功能及血清FGF-21、MMP-7的影响. 上海针灸杂志, 2021, 40(2): 152-156.
26.	李彬, 张一, 杨秦梅. 脐灸治疗肺脾气虚型特发性肺间质纤维化合并胃食管反流疗效观察. 中国针灸, 2019, 39(3): 241-245.

1. Maher TM, Bendstrup E, Dron L, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res, 2021, 22(1): 197.
2. Cox IA, Otahal P, de Graaff B, et al. Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in Australia. Respirology, 2022, 27(3): 209-216.
3. Strongman H, Kausar I, Maher TM. Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK. Adv Ther, 2018, 35(5): 724-736.
4. Cottin V, Spagnolo P, Bonniaud P, et al. Mortality and respiratory-related hospitalizations in idiopathic pulmonary fibrosis not treated with antifibrotics. Front Med (Lausanne), 2021, 8: 802989.
5. Gao J, Kalafatis D, Carlson L, et al. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry. Respir Res, 2021, 22(1): 40.
6. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med, 2018, 198(5): e44-e68.
7. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med, 2022, 205(9): e18-e47.
8. Dove EP, Olson AL, Glassberg MK. Trends in idiopathic pulmonary fibrosis-related mortality in the United States: 2000-2017. Am J Respir Crit Care Med, 2019, 200(7): 929-931.
9. Hopkins RB, Burke N, Fell C, et al. Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. Eur Respir J, 2016, 48(1): 187-195.
10. Raimundo K, Chang E, Broder MS, et al. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med, 2016, 16: 2.
11. Collard HR, Chen SY, Yeh WS, et al. Health care utilization and costs of idiopathic pulmonary fibrosis in U. S. Medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc, 2015, 12(7): 981-987.
12. 宣建伟, 卢永吉, 任懋东, 等. 中国特发性肺纤维化患者的直接经济负担. 中国药物经济学, 2019, 14(6): 9-12.
13. Li J, Yu XQ, Xie Y, et al. Efficacy and safety of traditional Chinese medicine treatment for idiopathic pulmonary fibrosis: an exploratory, randomized, double-blinded and placebo controlled trial. Front Pharmacol, 2022, 13: 1053356.
14. 中华中医药学会内科分会, 中国民族医药学会肺病分会, 中华中医药学会肺系病分会. 特发性肺纤维化中医证候诊断标准(2019版). 中医杂志, 2020, 61(18): 1653-1656.
15. 张立山, 戴雁彦, 任传云. 武维屏教授治疗肺纤维化十法. 中国中医药信息杂志, 2008, 15(4): 94-95.
16. 鞠铮嵘. 肺痿理论—晁恩祥名老中医治疗肺纤维化经验总结. 北京: 北京中医药大学, 2014.
17. 李建生. 特发性肺纤维化中医辨证治疗概要. 中医学报, 2017, 32(6): 929-931.
18. 徐慧卿. 针药并用治疗特发性肺纤维化疗效观察. 上海针灸杂志, 2010, 29(10): 641-642.
19. 李戎, 闫智勇, 李文军, 等. 针灸治疗特发性肺纤维化临床观察. 针灸临床杂志, 2004, (2): 13-14,59.
20. 王艳, 谢洋, 吉紫乐, 等. 中药离子导入辅助治疗特发性肺纤维化疗效与安全性的Meta分析. 中医学报, 2023, 38(3): 665-672.
21. 白文梅, 马红霞, 同立宏. 益气活血通络膏方治疗气虚血瘀型特发性肺纤维化60例疗效观察. 新疆中医药, 2018, 36(6): 7-8.
22. 杨柳, 成淑芳, 张树森, 等. 康益膏方治疗特发性肺纤维化60例. 光明中医, 2015, 30(7): 1449-1450.
23. 张树森, 杨柳, 董瑞. 珠及膏治疗特发性肺纤维化气阴两伤型临床观察. 中国中医药现代远程教育, 2019, 17(23): 69-71.
24. 刘香玉, 李怡良, 戈艳蕾, 等. 隔姜督灸联合阳和汤化裁治疗特发性肺间质纤维化临床观察. 云南中医中药杂志, 2021, 42(5): 31-34.
25. 周剑, 吴炳辰. 热敏灸联合药物对肺肾气虚型特发性肺纤维化患者肺功能及血清FGF-21、MMP-7的影响. 上海针灸杂志, 2021, 40(2): 152-156.
26. 李彬, 张一, 杨秦梅. 脐灸治疗肺脾气虚型特发性肺间质纤维化合并胃食管反流疗效观察. 中国针灸, 2019, 39(3): 241-245.

Chinese Journal of Evidence-Based Medicine

Latest ArticlesGuidelines for diagnosis and treatment of Chinese medicine on idiopathic pulmonary fibrosis

Abstract Full text Figures/Tables Video References Cited by

Format

Content